长春高新(000661.SZ)子公司卡麦角林片临床试验申请获得批准

Core Insights - Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the registration clinical trial application of Cabergoline tablets [1] Company Summary - Jinsai Pharmaceutical is developing Cabergoline tablets, a dopamine receptor agonist that effectively activates the dopamine D2 receptor [1] - The drug is classified as a Class 3 chemical drug and is intended for the treatment of hyperprolactinemia/pituitary prolactin adenoma [1]